CoQ10 and Statins: One Review Says No, One Says Barely

Q: Does CoQ10 help statin muscle pain?

The two systematic reviews of this question disagree, which is the honest answer. A 2020 meta-analysis in Atherosclerosis pooled 7 randomised trials with 321 patients and found a weighted mean difference of -0.42 on pain with a 95% confidence interval of -1.47 to 0.62 — an interval that includes no effect — concluding it "did not demonstrate that CoQ10 supplementation was beneficial." A 2025 meta-analysis in the Journal of Nutritional Science pooled 7 trials with 389 patients and found -0.96, 95% CI -1.88 to -0.03, p < 0.05, concluding CoQ10 "can reduce muscle pain." Note how close that upper bound is to zero. Both reviews were pooling trials of 35 to 76 people.

Q: Should I take CoQ10 with my statin?

That is a question for whoever prescribed the statin, and this is not a case where an article should substitute for that. What the evidence can tell you is the size of what is on offer: at best a modest reduction on a pain scale, from a literature of a few hundred patients, with two reviews split on whether the pooled effect clears zero at all. What it cannot offer is the thing that matters most — the 2020 review found no improvement in the proportion of patients who stayed on their statin, risk ratio 0.99. If muscle symptoms are making you consider stopping, the conversation with your prescriber is the intervention with evidence behind it.

Q: How much CoQ10 did the studies use?

Across the trials in the 2025 meta-analysis, doses ranged from 100 to 600 mg per day, for durations of 30 to 90 days. That sixfold spread in dose is part of why the pooled results are unstable: the trials are not testing the same intervention as each other, and none of them is large. Anyone quoting you a precise optimal CoQ10 dose for statin muscle symptoms is going well beyond what this literature can support, because the literature has not compared doses head to head in a trial big enough to tell them apart.

Q: What is the nocebo effect and why does it matter here?

It is when the act of taking a tablet produces genuine symptoms even though the tablet contains nothing active. It matters because two personalised n-of-1 trials, StatinWise and SAMSON, randomised individual patients to repeated alternating periods of statin, placebo and no treatment, and their authors report that together these trials "support the existence of a significant nocebo effect from taking statins." If a meaningful portion of the symptom burden is not produced by the statin molecule, then a supplement aimed at a statin mechanism is aimed at the wrong target — which may be exactly why its trials keep landing on both sides of zero.

Q: Is the famous "90% nocebo" statin figure real?

We are not going to repeat that number, and the reason is instructive. A widely shared ratio came out of the SAMSON trial, and members of that trial's own team have since written that the study "planned to report its results in terms of a 'nocebo ratio,' but statistical oversights invalidated this approach," adding that the authors also presented the difference in symptom scores alongside it. So the headline statistic that circulates most widely is one the researchers themselves stepped back from. The qualitative conclusion — that these trials support a significant nocebo effect — is what the same group still states, and that is what this page reports.

Q: Can I get back on a statin if I could not tolerate one before?

Often, yes, and this is the most hopeful finding in the whole area. Reporting on the StatinWise and SAMSON trials, the researchers write that "up to half of the patients in these trials were able to successfully restart statins after taking part, despite previously having been statin intolerant." The mechanism was not a supplement; it was a structured, personalised re-challenge that let each patient see their own symptom data across statin, placebo and no-treatment periods. That is something a prescriber can arrange in principle, and it is a far better use of three months than a capsule with a coin-flip evidence base.

Q: Are there safety concerns with CoQ10 itself?

CoQ10 is generally well tolerated in the trials described here, which ran 30 to 90 days at 100 to 600 mg daily, and neither review reported it as a safety problem. The genuine caution is interaction rather than toxicity: CoQ10 has been reported to interact with warfarin, and anyone on an anticoagulant should raise it before starting. More broadly, if you are taking a statin you are already under someone's care for cardiovascular risk, and that is the person who should know about anything you add. The risk on this page is not the capsule; it is a delayed appointment.

Q: Why do the two reviews disagree if they used the same trials?

Because the trials are small enough that inclusion decisions move the result. The 2020 review screened 413 records, selected 8 studies and pooled 7 of them covering 321 patients, of which only 2 individual studies showed a positive effect. The 2025 review searched Medline and the Cochrane Library to August 2024, pooled 7 trials covering 389 patients, and found 4 of 7 individually significant. Different search dates, slightly different pools, different totals. When every constituent trial has 35 to 76 participants, which ones you include and exclude can decide whether a pooled interval clears zero — and here it decided exactly that.

24 Aug 2026·HealthyMag Editorial Team

Two identical unlabelled white pill bottles side by side on a plain grey surface

Quick answer

Do not stop your statin over this page. With that said, the honest state of the evidence is stranger than either side of the argument admits. Two systematic reviews pooled almost the same small trials and reached opposite conclusions. A 2020 meta-analysis in Atherosclerosis combined 7 randomised trials with 321 patients and found no benefit: weighted mean difference -0.42 on pain, 95% CI -1.47 to 0.62, an interval straddling zero. A 2025 meta-analysis in the Journal of Nutritional Science combined 7 randomised trials with 389 patients and found a significant one: WMD -0.96, 95% CI -1.88 to -0.03, p < 0.05 — significant, but with an upper bound of -0.03, which is as close to zero as a significant result gets. In the 2020 review only 2 of 8 studies were positive; in the 2025 review 4 of 7 were. The entire literature is trials of 35 to 76 patients each. And there is a third finding that reframes the question: personalised n-of-1 trials, StatinWise and SAMSON, “support the existence of a significant nocebo effect from taking statins,” and up to half of the previously statin-intolerant patients in them successfully restarted statins afterwards. The one commercially useful claim — that CoQ10 helps you stay on your statin — was tested directly and failed: RR 0.99, 95% CI 0.81 to 1.20.

Statin-associated muscle symptoms are the most common reason people stop taking a drug that prevents heart attacks. CoQ10 is the most commonly suggested fix. So it matters that the evidence does not agree with itself.

Two reviews, same question, opposite answers

	Kennedy 2020	Kovacic 2025
Trials pooled	7	7
Patients	321	389
Individual trials positive	2 of 8 reviewed	4 of 7
Pooled effect on pain	-0.42	-0.96
95% CI	-1.47 to 0.62	-1.88 to -0.03
Verdict	no benefit	significant, p < 0.05

Look at the two confidence intervals rather than the two verdicts.

The 2020 interval runs from a meaningful benefit to a mild harm. The 2025 interval runs from a meaningful benefit to -0.03, which is effectively nothing. One review failed to exclude zero; the other excluded it by three hundredths of a point.

These are not two opposed bodies of evidence. They are two teams pooling overlapping sets of very small trials and landing on either side of a line.

How small is the evidence base

The 2025 review is explicit about the trials it pooled: 35 to 76 patients each, durations of 30 to 90 days, CoQ10 doses from 100 to 600 mg per day. The 2020 review describes the same range, 37 to 76 patients, published between 2007 and 2016.

So the total human evidence on a question asked by millions of people is a few hundred participants, dosed anywhere across a sixfold range, for one to three months.

That is why two competent teams can read it differently. It is also why the 2025 authors, having found a positive result, end with “more research is needed for evidence-based recommendations.”

The claim that was tested and failed

There is one outcome here that matters more than pain scores, because it is the outcome that would save lives: does CoQ10 help people keep taking their statin?

The 2020 review tested exactly that. The result:

CoQ10 did not improve the proportion of patients remaining on the statin treatment (RR 0.99; 95% CI, 0.81 to 1.20).

A risk ratio of 0.99. Identical to placebo, with a tight interval around it. Whatever CoQ10 does or does not do to a pain score, it did not keep anyone on their medication.

The question underneath the question

Here is the part that reframes all of it, and it comes from a different kind of study.

Two personalised n-of-1 trials — StatinWise and SAMSON — randomised individual patients to repeated alternating periods of statin, placebo and in SAMSON’s case no tablet at all, measuring symptom burden in each. Their authors’ summary:

“Together, these trials support the existence of a significant nocebo effect from taking statins.”

And the outcome that matters most:

“up to half of the patients in these trials were able to successfully restart statins after taking part, despite previously having been statin intolerant.”

If a substantial share of the symptom burden comes from the act of taking a tablet rather than from the drug in it, then CoQ10 is being asked to correct something whose cause is genuinely in dispute. That does not prove CoQ10 useless. It does explain why its trials are so unstable.

One honesty note that most coverage of SAMSON omits. A widely circulated “nocebo ratio” figure came out of that trial, and its own authors have since written that the trial “planned to report its results in terms of a ‘nocebo ratio,’ but statistical oversights invalidated this approach.” So this page does not quote that number. What survives is the qualitative finding above, stated by the same group.

What to actually do

Do not stop the statin on your own. The muscle symptoms are unpleasant; an unprevented heart attack is worse. This is the single most important sentence on the page.

Take the symptom to the prescriber, not to the supplement aisle. The options that have actual evidence behind them are things only they can do: change the statin, change the dose, change the schedule, or run a structured re-challenge. The n-of-1 literature exists precisely because that approach got half of previously intolerant patients back on treatment.

If you try CoQ10 anyway, know what you are buying. The tested range is 100 to 600 mg daily over one to three months, from trials of a few dozen people each, with two reviews disagreeing about whether the pooled result crosses zero. That is a coin-flip dressed as a protocol, and it did nothing for adherence.

And do not let it delay the conversation. Three months of a supplement is three months of either symptoms or an unmanaged statin problem.

Why there is no product link on this page

Because the conclusion does not support a purchase, and because of what this page is about.

The reviews disagree, the positive one’s confidence interval stops three hundredths short of nothing, and the outcome with real stakes — staying on the drug — came back at RR 0.99. Selling a supplement on the back of that, to people deciding whether to keep taking a cardiovascular medicine, would be the worst possible page on which to earn a commission.

We place links where a specific thing follows from what the evidence showed. Here what follows is an appointment.

The short version

Two systematic reviews. Same question, overlapping trials, opposite verdicts, and a positive result whose interval ends at -0.03. A total literature of a few hundred patients in trials of 35 to 76. No effect on whether anyone stayed on their statin. And an n-of-1 literature suggesting a significant share of the symptoms is nocebo, alongside evidence that structured re-challenge got up to half of intolerant patients back on treatment.

The useful move is not a capsule. It is the appointment where someone changes the statin, the dose, or the schedule.

Frequently Asked Questions

Does CoQ10 help statin muscle pain?

The two systematic reviews of this question disagree, which is the honest answer. A 2020 meta-analysis in Atherosclerosis pooled 7 randomised trials with 321 patients and found a weighted mean difference of -0.42 on pain with a 95% confidence interval of -1.47 to 0.62 — an interval that includes no effect — concluding it “did not demonstrate that CoQ10 supplementation was beneficial.” A 2025 meta-analysis in the Journal of Nutritional Science pooled 7 trials with 389 patients and found -0.96, 95% CI -1.88 to -0.03, p < 0.05, concluding CoQ10 “can reduce muscle pain.” Note how close that upper bound is to zero. Both reviews were pooling trials of 35 to 76 people.

Should I take CoQ10 with my statin?

That is a question for whoever prescribed the statin, and this is not a case where an article should substitute for that. What the evidence can tell you is the size of what is on offer: at best a modest reduction on a pain scale, from a literature of a few hundred patients, with two reviews split on whether the pooled effect clears zero at all. What it cannot offer is the thing that matters most — the 2020 review found no improvement in the proportion of patients who stayed on their statin, risk ratio 0.99. If muscle symptoms are making you consider stopping, the conversation with your prescriber is the intervention with evidence behind it.

How much CoQ10 did the studies use?

Across the trials in the 2025 meta-analysis, doses ranged from 100 to 600 mg per day, for durations of 30 to 90 days. That sixfold spread in dose is part of why the pooled results are unstable: the trials are not testing the same intervention as each other, and none of them is large. Anyone quoting you a precise optimal CoQ10 dose for statin muscle symptoms is going well beyond what this literature can support, because the literature has not compared doses head to head in a trial big enough to tell them apart.

What is the nocebo effect and why does it matter here?

It is when the act of taking a tablet produces genuine symptoms even though the tablet contains nothing active. It matters because two personalised n-of-1 trials, StatinWise and SAMSON, randomised individual patients to repeated alternating periods of statin, placebo and no treatment, and their authors report that together these trials “support the existence of a significant nocebo effect from taking statins.” If a meaningful portion of the symptom burden is not produced by the statin molecule, then a supplement aimed at a statin mechanism is aimed at the wrong target — which may be exactly why its trials keep landing on both sides of zero.

Is the famous “90% nocebo” statin figure real?

We are not going to repeat that number, and the reason is instructive. A widely shared ratio came out of the SAMSON trial, and members of that trial’s own team have since written that the study “planned to report its results in terms of a ‘nocebo ratio,’ but statistical oversights invalidated this approach,” adding that the authors also presented the difference in symptom scores alongside it. So the headline statistic that circulates most widely is one the researchers themselves stepped back from. The qualitative conclusion — that these trials support a significant nocebo effect — is what the same group still states, and that is what this page reports.

Can I get back on a statin if I could not tolerate one before?

Often, yes, and this is the most hopeful finding in the whole area. Reporting on the StatinWise and SAMSON trials, the researchers write that “up to half of the patients in these trials were able to successfully restart statins after taking part, despite previously having been statin intolerant.” The mechanism was not a supplement; it was a structured, personalised re-challenge that let each patient see their own symptom data across statin, placebo and no-treatment periods. That is something a prescriber can arrange in principle, and it is a far better use of three months than a capsule with a coin-flip evidence base.

Are there safety concerns with CoQ10 itself?

CoQ10 is generally well tolerated in the trials described here, which ran 30 to 90 days at 100 to 600 mg daily, and neither review reported it as a safety problem. The genuine caution is interaction rather than toxicity: CoQ10 has been reported to interact with warfarin, and anyone on an anticoagulant should raise it before starting. More broadly, if you are taking a statin you are already under someone’s care for cardiovascular risk, and that is the person who should know about anything you add. The risk on this page is not the capsule; it is a delayed appointment.

Why do the two reviews disagree if they used the same trials?

Because the trials are small enough that inclusion decisions move the result. The 2020 review screened 413 records, selected 8 studies and pooled 7 of them covering 321 patients, of which only 2 individual studies showed a positive effect. The 2025 review searched Medline and the Cochrane Library to August 2024, pooled 7 trials covering 389 patients, and found 4 of 7 individually significant. Different search dates, slightly different pools, different totals. When every constituent trial has 35 to 76 participants, which ones you include and exclude can decide whether a pooled interval clears zero — and here it decided exactly that.

Sources

Kennedy C, Köller Y, Surkova E. Effect of coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: a systematic review and meta-analysis. Atherosclerosis 2020 Apr;299:1-8. PMID 32179207. DOI 10.1016/j.atherosclerosis.2020.03.006. 413 records identified; 8 studies selected for review and 7 (321 patients) included in the meta-analysis; studies published between 2007 and 2016 with participant numbers ranging from 37 to 76. Verbatim: “Only two of these studies demonstrated a positive effect of CoQ10 therapy in relieving muscle pain. The meta-analysis did not demonstrate any benefit of CoQ10 supplementation in improving myalgia symptoms compared to placebo (weighted mean difference -0.42; 95% Confidence Interval [CI] -1.47 to 0.62). Similarly, CoQ10 did not improve the proportion of patients remaining on the statin treatment (RR 0.99; 95%CI, 0.81 to 1.20).” Authors declared no conflicts of interest. Checked 24 August 2026. https://pubmed.ncbi.nlm.nih.gov/32179207/
Kovacic S, Habicht SD, Eckert GP. Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis. Journal of Nutritional Science 2025 Oct 10;14:e72. PMID 41158831. DOI 10.1017/jns.2025.10043. Literature search of Medline and the Cochrane Library performed August 2024. Seven RCTs with 389 patients in total; included studies had 35 to 76 patients, durations of 30 to 90 days, and CoQ10 dosages of 100 to 600 mg per day. Verbatim: “Results show a significant reduction of SAMS in four trials and no significant change in three trials. Overall, a significant reduction in SAMS, measured as pain intensity, after CoQ10 supplementation was found: weighted mean difference (WMD) -0.96 (95% Confidence Interval -1.88; -0.03), p < 0.05” and “Supplementation of CoQ10 can reduce muscle pain in patients with SAMS, which is relevant for their well-being and treatment continuation. More research is needed for evidence-based recommendations.” Authors declare no conflict of interest. Cited alongside the 2020 review rather than instead of it, because the two reach opposite verdicts on overlapping evidence. Checked 24 August 2026. https://pubmed.ncbi.nlm.nih.gov/41158831/
Howard JP, Wood FA, Francis DP. Why do I get side effects? Personalized (N-of-1) trials for statin intolerance and the nocebo effect. Harvard Data Science Review 2022;2022:10.1162/99608f92.abc57f1b. PMID 38344133. PMCID PMC10857873. Verbatim: “Two recent randomized placebo-controlled personalized (N-of-1) trials have been reported: StatinWise and SAMSON… Together, these trials support the existence of a significant nocebo effect from taking statins. Possibly even more importantly, they demonstrate the ability of personalized trials to inform and empower patients: up to half of the patients in these trials were able to successfully restart statins after taking part, despite previously having been statin intolerant.” Also verbatim, and the reason this page quotes no nocebo ratio: “The SAMSON trial planned to report its results in terms of a ‘nocebo ratio,’ but statistical oversights invalidated this approach, and the study authors also presented the difference in symptom scores alongside this.” Checked 24 August 2026. https://pubmed.ncbi.nlm.nih.gov/38344133/
Wood FA, Howard JP, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, Rajkumar CA, Connolly S, Cegla J, Stride C, Sever P, Norton C, Thom SAM, Shun-Shin MJ, Francis DP. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. New England Journal of Medicine 2020 Nov 26;383(22):2182-2184. PMID 33196154. DOI 10.1056/NEJMc2031173. This is the SAMSON trial itself, cited for identification and provenance. Its numerical findings are reported on this page only as characterised by its own authors in the 2022 source above, because of the stated statistical problem with its planned primary measure. Checked 24 August 2026. https://pubmed.ncbi.nlm.nih.gov/33196154/

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any health decisions. Content reviewed by the HealthyMag Editorial Team.